CNSide Diagnostics schedules a conference call for September 30, 2026, to discuss business updates and recent developments.
Quiver AI Summary
CNSide Diagnostics, LLC, a subsidiary of Cerenome, Inc., announced a conference call and webcast scheduled for September 30, 2026, at 8:30 a.m. Eastern Time to provide an update on its CNSide® cerebrospinal fluid diagnostic platform. The discussion will cover recent advancements in commercial operations, including third-party billing, market access, and expansion of the commercial team, as well as the enrichment of their diagnostic testing portfolio. Dr. Marc H. Hedrick, Cerenome’s President and CEO, emphasized the progress made since the platform's launch in early 2026 and the opportunity for stakeholders to learn about these developments and the company’s goals. CNSide Diagnostics focuses on laboratory-developed tests to identify tumor cells in cerebrospinal fluid, aimed at improving patient management for central nervous system cancers.
Potential Positives
- Management will provide a business update on the CNSide® diagnostic platform, indicating transparency and engagement with stakeholders.
- The focus on positive commercial developments, including third-party billing and market access, demonstrates the potential for revenue growth and business expansion.
- The announcement of a conference call and webcast suggests proactive communication with the investment community, which can enhance investor confidence.
- CNSide® is designed to improve patient management in CNS oncology, highlighting the company's commitment to addressing significant medical needs in this field.
Potential Negatives
- Management's need to host a conference call and provide updates suggests previous communication may not have effectively addressed shareholder concerns or market expectations.
- The emphasis on 'recent commercial related developments' may indicate previous challenges in the commercialization process of the CNSide® platform.
- Use of 'forward-looking statements' implies uncertainty regarding the company's future performance and market projections, which may raise concerns among investors about the viability of their strategies.
FAQ
What is CNSide Diagnostics, LLC?
CNSide Diagnostics, LLC is a subsidiary of Cerenome, Inc. focused on developing proprietary diagnostic tests for CNS cancers.
When is the upcoming conference call for CNSide Diagnostics?
The conference call is scheduled for September 30, 2026, at 8:30 a.m. Eastern Time.
How can I access the webcast for the conference call?
You can access the webcast through the link provided in the press release or visit Cerenome’s website.
What is the CNSide® CSF Assay Platform?
The CNSide® CSF Assay Platform analyzes cerebrospinal fluid to help manage cases of leptomeningeal metastases in cancer patients.
What are Cerenome’s goals for 2026?
Cerenome aims to expand its commercial team, enhance market access, and broaden its diagnostic testing portfolio by 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY ) (“Cerenome” or the “Company”), today announced that management will host a conference call and webcast on Wednesday, September 30, 2026, at 8:30 a.m. Eastern Time to provide a business update on CNSide ® , the Company's cerebrospinal fluid (CSF) diagnostic platform, offered through its wholly owned subsidiary, CNSide Diagnostics, LLC. The update will focus on recent commercial related developments including third-party billing, market access, expansion of the commercial team and broadening of the diagnostic testing portfolio.
“Our CNSide Diagnostics team has made tremendous progress since we launched CNSide in early 2026,” said Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer. “We would like to provide our stockholders and the broader capital markets community the opportunity to learn more about positive recent developments, progress to 2026 goals and plans to grow and expand the business.”
Conference Call and Webcast
| Date | Wednesday, September 30, 2026 |
| Time | 8:30 a.m. Eastern Time |
| Webcast | Click here to access the webcast |
| Dial-in (U.S./Canada) | 877-270-2148 |
| Dial-in (International) | 412-902-6510 |
A replay of the webcast will be available following the conclusion of the event in the Investor Relations section of the Company's website at www.cerenome.com .
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide
®
, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide
®
CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit
https://www.cnside-dx.com/
.
About Cerenome
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide
®
Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value, visit
https://www.cerenome.com
.
Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.
Investor Contact
CORE IR
[email protected]
